WEEKLY INJECTION · GLP-1 + GIP
Zepbound®
Tirzepatide 2.5–15 mg
21%
avg. body weight lost in trials
Tirzepatide activates both GLP-1 and GIP receptors — a dual mechanism that slows gastric emptying, reduces cravings, and helps the body break down stored fat more efficiently than single-receptor medications.
How It Works
Tirzepatide activates both GLP-1 and GIP receptors — a dual mechanism that slows gastric emptying, reduces cravings, and helps the body break down stored fat more efficiently than single-receptor medications.
Expected Results
Patients experienced up to 22% weight loss with tirzepatide. A study of 18,000 participants showed tirzepatide (42%) was more effective than semaglutide (18%) in achieving ≥15% weight loss. Also FDA-approved for obstructive sleep apnea.
Common Side Effects
Nausea, vomiting, constipation, diarrhea, bloating, gas, gastritis, and fatigue — typically most pronounced during initiation and dose escalation.
Who Should Avoid
Individuals with personal or family history of Medullary Thyroid Cancer (MTC) or MEN2 Syndrome. Those who are pregnant, breastfeeding, or trying to conceive.
This information is for educational purposes only and does not replace medical advice from your physician. Individual results vary. Always discuss side effects, contraindications, and treatment options during your consultation.